Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. (2016)

First Author: Harrison CN
Attributed to:  Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1080/10428194.2016.1195501

PubMed Identifier: 27463690

Publication URI: http://europepmc.org/abstract/MED/27463690

Type: Journal Article/Review

Volume: 57

Parent Publication: Leukemia & lymphoma

Issue: 10

ISSN: 1026-8022